1,721,248 research outputs found
Hormone replacement after breast cancer. A consensus recommendation
No full textWomen with treated breast cancer who wish to undergo hormone replacement therapy (HRT), or in whom sequelae of estrogen deficiency can be expected, should be informed about the available alternative treatments. HRT should be considered only in the case of a severe lowering of the quality of life by climacteric symptoms that cannot be controlled by other means, including modification of lifestyle. Before the commencement of HRT every patient must be informed in full about her individual constellation of potential benefits and risks, and if appropriate the treating oncologist should be consulted. These steps must be documented. HRT in breast cancer patients should be conducted with the lowest possible dosage and discontinued at the earliest possible time
Is chemotherapy a new standard in the adjuvant treatment of stage II and IV endometrial cancer?
No full textHormone therapy with estrogens and gestagens in peri- and post-menopause
No full textHormone therapy with estrogens (combined with progestin for women who have not been hysterectomized) is the most efficacious treatment for climacteric symptoms. A few years ago hormone therapy was considered to be an ideal prevention for cardio-vascular disease, osteoporosis, dementia and other diseases. Large prospective randomized trials have changed this paradigm. Hormone therapy should only be used with a clear indication (moderate to severe climacteric symptoms and - with limitations - prevention of osteoporosis). The lowest effective dose should be used for the shortest possible time
Is lymphadenectomy still a relevant procedure in the treatment of endometrial cancer?
No full textThe role of pelvic and para-aortic lymphadenectomy (LNE) in endometrial cancer (EC) is currently a matter of debate. It has been recommended by the International Federation of Gynecology and Obstetrics (FIGO) for staging purposes to allow a risk-adjusted adjuvant (radio) therapy. Many experts are convinced that it has a therapeutic impact by removing tumor metastases. In low risk EC (type 1 histology, 90%) in the absence of LNE and radiotherapy. In type 2 or G3 EC and those of higher stages (a parts per thousand yenaEuro parts per thousand pT1b) lymph node metastases are more frequent. In patients with these tumors the results of total hysterectomy plus bilateral salpingo-oophorectomy plus external beam radiotherapy are unsatisfactory. In these patients systematic pelvic and para-aortic LNE is probably beneficial
Response of the Uterus Commission of AGO to the Comment of M. Kolben, C. Dannecker and R. Kurzl
No full textHormonal treatment of endometrial cancer
No full textIn developed western countries endometrial cancer is the most common malignant tumor of the female genital tract. 75% of cases are diagnosed in stage I where cure rates of 75-90% are achieved. In stage II, 5-year survival rates amount only to 50%, in stage III up to 30%, and in stage IV to less than 10%. Despite the preponderance of early stage endometrial cancer, about 20-30% of affected patients will die from this disease. As surgical treatment and/or irradiation are not able to control advanced disease, many investigators have been searching for systemic treatment modalities. Cytotoxic chemotherapy achieves high initial response rates of about 40-60%. Recurrence, however, occurs after a median duration of only a few months. As endometrial cancer develops from hormone dependent cells, endocrine treatment has been the traditional palliative therapy of advanced tumor stages. Several studies to dale have failed to demonstrate an efficacy of adjuvant hormonal therapy in cases of high-risk endometrial cancer. For the conservative treatment of precancerous, non-invasive hyperplastic lesions of the endometrium, endocrine therapies have been shown to be efficacious
- …
